Priv.-Doz. Dr. med. Christian Labenz

Diagnostik und Therapie bei akuten und chronischen Lebererkrankungen mit den Schwerpunkten:

• Komplikationen der Leberzirrhose (Schwerpunkte: hepatische Enzephalopathie und hepatorenales Syndrom),
• Evaluation neuer Diagnosestrategien zur Detektion der hepatischen Enzephalopathie,
• Translationale Biomarkerentwicklung zur Detektion und Prognoseabschätzung von Komplikationen der Leberzirrhose,
• Frailty (Gebrechlichkeit) bei PatientInnen mit Leberzirrhose,
• Nicht-alkoholische Fettlebererkrankung (NAFLD),
• Konzeption und Durchführung klinischer Studien.

• Dr. med. Simon J. Gairing
• Dr. med. Eva M. Schleicher
• Dr. rer. nat. et med. Leonard Kaps
• Christian M. Reinhardt
• Teresa Braun
• Nathalie Eckel

• Prof. Dr. med. Jörn M. Schattenberg (I. Medizinische Klinik und Poliklinik, Universitätsmedizin Mainz),
• PD Dr. med. Felix Lüssi (Klinik und Poliklinik für Neurologie, Universitätsmedizin Mainz),
• Prof. Dr. med. Philipp Wild und Dr. Thomas Köck (Präventive Kardiologie und Medizinische Prävention, Zentrum für Kardiologie, Universitätsmedizin Mainz),
• Prof. Dr. med. Jens U. Marquardt (Medizinische Klinik I, Universitätsklinikum Schleswig-Holstein Campus Lübeck),
• Prof. Dr. med. Marcus-Alexander Wörns (Klinik für Gastroenterologie, Hämatologie, internistische Onkologie und Endokrinologie, Klinikum Dortmund),
• Prof. Dr. Mette Munk Lauridsen (Department of Gastroenterology and Hepatology, Hospital of Southwest Jutland, Esbjerg, Dänemark),
• Prof. Dr. Sara Montagnese (Department of Gastroenterology and Hepatology, Padova University Hospital, Italy),
• Prof. Dr. Patricia P. Bloom (University of Michigan, Ann Arbor, USA).

1.    Gairing S.J., Mangini C., Zarantonello L., Gioia S., Nielsen E.J., Danneberg S., Gabriel M., Ehrenbauer A.F., Bloom P.P., Ripoll C., Sultanik P., Galle P.R., Labenz J., Thabut D., Zipprich A., Lok A.S., Weissenborn K., Marquardt J.U., Lauridsen M.M., Nardelli S., Montagnese S., Labenz C.; Prevalence of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis: A Multicenter Study; American Journal of Gastroenterology. 2023; doi: 10.14309/ajg.0000000000002251.

2.    Gairing S.J., Danneberg S., Kaps L., Nagel M., Schleicher E.M., Quack C., Engel S., Bittner S., Galle P.R., Schattenberg J.M., Wörns M.-A., Luessi F., Marquardt J.U., Labenz C.; Elevated serum levels of glial fibrillary acidic protein are associated with covert hepatic encephalopathy in patients with cirrhosis; JHEP Reports. 2023; 5(4):100671.

3.    Schleicher E.M., Kremer W.M., Kalampoka V., Gairing S.J., Kaps L., Schattenberg J.M., Galle P.R., Wörns M.-A., Nagel M., Weinmann-Menke J., Labenz C.; Frailty as tested by the Clinical Frailty Scale is a risk factor for hepatorenal syndrome in patients with liver cirrhosis; Clinical and Translational Gastroenterology. 2022; 13(7):e00512.

4.    Schleicher E.M., Gairing S.J., Galle P.R., Weinmann-Menke J., Schattenberg J.M., Kostev K., Labenz C.; A higher FIB-4 index is associated with an increased incidence of renal failure in the general population; Hepatology Communications. 2022; 6(12):3505-3514.

5.    Labenz C.*, Arslanow A.*, Nguyen-Tat M., Nagel M., Wörns M.-A., Reichert M.C., Heil F.J., Mainz D., Zimper G., Römer B., Binder H., Farin-Glattacker E., Fichtner U., Graf E., Stelzer D., Von Ewijk R., Ortner J., Velthuis L., Lammert F., Galle P.R.; Structured Early detection of Asymptomatic Liver Cirrhosis: Results oft he population-based liver screening program SEAL; Journal of Hepatology. 2022, 77(3):695-701.

6.    Kaps L., Omogbehin L., Hildebrand K., Gairing S.J., Schleicher E.M., Moehler M., Rahman F., Schattenberg J.M., Wörns M.A., Galle P.R., Labenz C.; Health literacy in gastrointestinal diseases: a comparative analysis between pantients with liver cirrhosis, inflammatory bowl disease and gastrointestinal cancer; Scientific Reports. 2022; 12(1):21072.

7.    Kaps L., Hildebrand K., Nagel M., Michel M., Kremer W.M., Hilscher M., Galle P.R., Schattenberg J.M., Wörns M.-A., Labenz C.; Validation of EncephalApp_stroop as screening tool for the detection of minimal hepatic encephalopathy in German patients with liver cirrhosis; Clin Res Hepatol Gastroenterol. 2022; 3:101873.

8.    Gairing S.J., Anders J., Kaps L., Nagel M., Michel M., Kremer W.M., Hilscher M., Galle P.R., Schattenberg J.M., Wörns M.-A., Labenz C.; Evaluation of IL-6 for stepwise diagnosis of minimal hepatic encephalopathy in patients with liver cirrhosis; Hepatology Communications. 2022; 6(5):1113-1122.

9.    Labenz C., Toenges G., Zheng M.H., Ding D., Myers R.P., Galle P.R., Armandi A., Ampuero J., Gomez M.R., Bugianesi E., Anstee Q.M., Schattenberg J.M.; Derivation and validation of the nonalcoholic fatty liver disease cirrhosis score (NCS) to distinguish bridging fibrosis from cirrhosis; Eur J Intern Med. 2022; 98:53-60.

10. Labenz C., Nagel M., Kämper P., Engel S., Bittner S., Kaps L., Galle P.R., Schattenberg J.M., Wörns M.-A., Lüssi F.; Association Between Serum Levels of Neurofilament Light Chains and Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis; Clinical and Translational Gastroenterology. 2021; 12(10): e00419.

11. Labenz C.*, Nagel M.*, Toenges G., Kuchen R., Schattenberg J.M., Hilscher M., Huber Y., Marquardt J.U., Labenz J., Galle P.R., Wörns M.-A.; Impact of non-selective ß-blockers on hepatic encephalopathy in patients with liver cirrhosis. Eur J Intern Med. 2020; S0953-62205(20)30344-7.

12. Labenz C., Wörns M.-A., Adarkwah C.C., Galle P.R., Schattenberg J.M., Kostev K.; Proton pump inhibitors increase risk of bone fractures in men with cirrhosis: a population-based study. Aliment Pharmacol Ther. 2020; 52(6):1042-1050.

13. Labenz C., Nagel M., Kremer W.M., Hilscher M., Schilling C.A., Toenges G., Kuchen R., Schattenberg J.M., Galle P.R., Wörns M.-A.; Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosis. Aliment Pharmacol Ther. 2020; 52(3):527-536.

14. Labenz C., Toenges G., Schattenberg J.M., Nagel M., Huber Y., Marquardt J.U., Labenz J., Galle P.R. Wörns M.-A.; Outcome Prediction of Covert Hepatic Encephalopathy in Liver Cirrhosis: Comparison of Four Testing Strategies. Clin Transl Gastroenterol. 2020; 11(6):e00172.

15. Labenz C., Toenges G., Schattenberg J.M., Nagel M., Huber Y., Marquardt J.U., Galle P.R., Wörns M.-A.; Health-related quality of life in patients with compensated and decompensated liver cirrhosis; Eur J Intern Med. 2019; 70:54-59.

16. Labenz C., Toenges G., Huber Y., Nagel M., Marquardt J.U., Schattenberg J.M., Galle P.R., Labenz J., Wörns M.-A.; Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy; Aliment Pharmacol Ther. 2019; 50(10):1112-1119.

17. Labenz C., Toenges G., Huber Y., Nagel M., Marquardt J.U., Schattenberg J.M., Galle P.R., Labenz J., Wörns M.-A.; Development and validation of a prognostic score to predict covert hepatic encephalopathy in cirrhotic patients; American Journal of Gastroenterology. 2019; 114(5):764-770.

18. Labenz C., Huber Y., Kalliga E., Nagel M., Ruckes C., Straub B.K., Galle P.R., Wörns M.-A., Anstee Q.M., Schuppan D., Schattenberg J.M.; Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany; Aliment Pharmacol Ther. 2018; 48(10):1109-1116.

19. Labenz C., Beul L., Toenges G., Schattenberg J.M., Nagel M., Sprinzl M.F., Nguyen-Tat M., Zimmermann T., Huber Y., Marquardt J.U., Galle P.R., Wörns M.-A.; Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy; Eur J Intern Med. 2019; 60:96-100.

20. Labenz C., Baron J.S., Toenges G., Schattenberg J.M., Nagel M., Sprinzl M.F., Nguyen-Tat M., Zimmermann T., Huber Y., Marquardt J.U., Galle P.R., Wörns M.-A.; Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients; Aliment Pharmacol Ther. 2018; 48(3):313-321.

• The Lancet Gastroenterology & Hepatology
• Gastroenterology
• eClinicalMedicine
• Clinical Gastroenterology and Hepatology
• Liver INTERNATONAL
• mBio
• HEPATOLOGY COMMUNICATIONS
• Scientific Reports
• BMC Gastroenterology, Therapeutic Advances in Gastroenterology
• PloS One
• Journal of Digestive Diseases 

u.v.m.

•  Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und 
   Stoffwechselerkrankungen (DGVS)
•  Berufsverband Deutscher Internistinnen und Internisten (BDI)
•  European Association for the Study of the Liver (EASL)
•  American Association for the Study of Liver Diseases (AASLD)
•  German Association for the Study of the Liver (GASL)
•  Gastroenterologische Arbeitsgemeinschaft Rheinland-Pfalz/Saar (GARPS)